anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Apply 200 mg liquid (approximately 0.2 mL) directly to tissue. Liquid in excess of 400 mg (approximately 0.4 mL) is contraindicated.

To apply, remove and discard the shipping cap from the bottle. Replace it with the supplied Luer-lock cap. Caution: Do not over-tighten. Remove small cap from luer-lock port, retaining it for replacement after use. Port allows for a single dip of a cotton or brush applicator for application directly to accessible mucous membrane. For application into periodontal pockets, Cetylite Luer-lock syringes and Microcapillary Delivery Tips are recommended. Cetylite Syringes are clearly marked in (4) 0.1 mL increments. To fill, attach syringe to port by gently twisting clockwise until secure. Invert and draw desired amount of liquid into the syringe. Remove filled syringe and attach Microcapillary Delivery Tip to the syringe. Tip may be bent to improve access. Apply drop-wise to accessible mucous membrane (such as buccal and lingual sulcus) by slowly depressing the syringe plunger. Discard all applicators after use.

An appropriate pediatric dosage has not been established for Cetacaine Spray or Cetacaine Liquid.

Dosages should be reduced in the debilitated elderly, acutely ill, and very young patients (i.e., children 2 years and older).

Do not use Cetacaine Spray or Cetacaine Liquid to treat infants or children younger than 2 years.

Tissue need not be dried prior to application of Cetacaine. Cetacaine should be applied directly to the site where pain control is required. Anesthesia is produced within one minute with an approximate duration of thirty minutes. Each 200 mg dose of Cetacaine (Spray or Liquid) contains 28 mg of benzocaine, 4 mg of butamben and 4 mg of tetracaine HCl.
Enclomiphene 12.5 milligram (mg) capsule daily in the morning with approximately 8 ounces of water for up to 12 months. Participant followed a commercial diet plan and exercised with a personal trainer at least 3 times a week.
The invention relates to a lip or care stick which contains vitamins and which is used for cosmetic applications. The stick contains an outer complex comprised of a cellulose derivative having a particle size ranging from 0.5 to 100  mu m, and is comprised of a phospholipid and of an  alpha -tocopherol ester. The proportion of the complex is equal to 0.5 to 40 wt. %, with regard to the total mass. The stick also contains cosmetically conventional fats, waxes and additives which have a proportion ranging from 99.5 to 60 wt. %.  alpha -tocopherol is stabilized with regard to UV-filters, can also be dissolved in the form of the complex by moisture and can be absorbed and processed as a vitamin by the body.
PURPOSE: The atherogenic index of plasma (AIP) is a novel comprehensive lipid index. We aimed to investigate a possible relationship between AIP index and kidney stones in US adults.
METHODS: This cross-sectional study was conducted among adults with complete AIP index and questionnaire records on kidney stones from the National Health and Nutrition Examination Survey (NHANES) spanning from 2007 to 2018. The AIP index served as the exposure variable, defined as the logarithm of the ratio between triglycerides (TG, mmol/L) and high-density lipoprotein cholesterol (HDL-c, mmol/L). Self-reported history of kidney stones was utilized as the outcome variable. The independent relationship between AIP index and the risk of kidney stones was fully assessed.
RESULTS: A total of 14,833 participants were included in this study, with an average AIP index of -0.07 ± 0.01. The proportion of kidney stones progressively increased with higher AIP index tertile intervals (7.33% vs. 9.97% vs. 12.57%, P < 0.001). Furthermore, AIP index was found to be independently associated with the risk of kidney stones after adjusting for confounding factors (OR = 1.32, 95% CI 1.08-1.61, P = 0.006). Restricted cubic spline (RCS) analysis confirmed the robustness of our results. There was no significant interaction observed based on subgroup analysis stratified by age, gender, race, body mass index (BMI, kg/m2), smokers, diabetes, hypertension, and cardiovascular disease (P for interaction > 0.05).
CONCLUSIONS: The AIP index may be a potential epidemiological tool to quantify the role of dyslipidemia in the risk of kidney stones in US adults.
Background: Sump syndrome is one of the rare long-term complications of side-to-side choledochoduodenostomy (CD) leading to attacks of cholangitis due to accumulation of food and debris in the common bile duct distal to the anastomosis is one of the rare long-term complications after CD. Methods: Fifteen patients treated with the Sump syndrome in our institution between 1996 and 2023 were retrospectively evaluated for long-term outcome. Results: Endoscopic retrograde cholangiopancreatography (ERCP) with sphincterotomy and bile duct clearance was done in 11 patients, while four were subjected to revisional surgery in the form of a Roux-en-Y hepaticojejunostomy. No complications were recorded. There were 5 (38%) recurrences in a median follow-up period of 8 years (10 months-23 years). Of those, 3 patients were treated surgically and two with repeat ERCP. None of the patients developed any cholangiocarcinoma during follow-up. Conclusion: We conclude that although a high recurrence rate was observed, endoscopic treatment may be a valid approach in the treatment of Sump syndrome, with revisional surgery in the form of a Roux-en-Y hepaticojejunostomy as salvage therapy in recurrences.
AIMS: To determine risk factors for 1-year postpartum weight retention (PPWR) and glucose intolerance (prediabetes + diabetes) in women with a previous history of gestational diabetes (GDM) and prediabetes in early postpartum.
METHODS: In this exploratory analysis of the MELINDA randomized controlled trial, we report data of 167 women with prediabetes at the 6-16 weeks (early) postpartum oral glucose tolerance test after a recent history of GDM.
RESULTS: Of all participants, 45% (75) had PPWR >0 kg at 1-year postpartum. Compared to women without PPWR, women with PPWR had higher gestational weight gain [10.5 ± 6.4 vs. 6.5 ± 4.5 kg, p < 0.001], higher BMI (p < 0.01) and a worse metabolic profile (higher waist circumference, worse lipid profile and more insulin resistance) (all p < 0.05) both in early and late postpartum. Of all women with PPWR, 40.0% developed metabolic syndrome, compared to 18.9% of women without late PPWR (p = 0.003). The only independent predictor for late PPWR was weight retention in early postpartum (p < 0.001). Of all participants, 55.1% (92) had glucose intolerance (84 prediabetes, 8 diabetes) 1-year postpartum. Independent predictors for late postpartum glucose intolerance were lower gestational age at start insulin therapy in pregnancy and delivery by caesarean section (resp. p = 0.044 and 0.014).
CONCLUSIONS: In women with a previous history of GDM and prediabetes in early postpartum, PPWR in early postpartum was a strong independent predictor for late PPWR, while earlier start of insulin therapy during pregnancy and delivery by caesarean section were independent predictors of glucose intolerance in late postpartum.
The invention relates to powder for external use for controlling infantile recurrent respiratory tract infection. Respiratory tract infection is caused by various viruses, and is divided into viral infection of the upper respiratory tract and viral lower respiratory tract infection. The viral infection of the upper respiratory tract is manifested by acute rhinitis, pharyngitis and laryngitis, and the viral lower respiratory tract infection is manifested by acute trachitis, bronchitis and pneumonia. The diseases have high morbidity, can easily infect people generally and more easily infect children, the old, malnourished people and people with chronic illnesses. The incidence of the diseases is high in spring and winter. Many respiratory infections, such as measles, rubella and the like, can be manifested as symptoms of upper respiratory infection. The infantile respiratory tract infection is difficult for treating especially, recurrently attacks. The present medicines are medicines for treating, however, the preventing should be first.
In the present study, the effects of levamlodipine benzenesulfonate on the development of fertile Sprague-Dawley (SD) rats, their embryos, and littermates were assessed using an embryo-fetal developmental toxicity test. Maternal body weight reduction was observed at a dose of 20 mg/kg, but it recovered after treatment cessation. The 20 mg/kg dose group showed a skewed sex ratio in fetal rats, with a higher proportion of males. While some effects on fetal sternum development were observed at 20 mg/kg, no skeletal malformations were observed. No significant gross morphological abnormalities were detected in the dams (mothers), no significant embryotoxicity or foetotoxicity in fetal rats and no significant effects on fetal length and weight development at doses of 5 and 10 mg/kg. Genotoxicity was evaluated using a combination of the Ames test, the Chinese hamster ovary (CHO) cell chromosome aberration assay, and the ICR mouse bone marrow micronucleus test. The Ames test results indicated substantial bacteriostatic effects at doses of 500 and 5000 mg/dish, with no mutagenicity observed at doses of 0.5, 5, and 50 mg/dish. No significant effect on the aberration rate of CHO cell chromosomes was found at doses of 2.8, 5.6, and 11.2 mg/mL. In the ICR mouse micronucleus test, no micronucleus-inducing effect was observed at doses of 3.125, 6.25, and 12.5 mg/kg in each treatment group. In conclusion, under the conditions of this experiment, the no-observed-adverse-effect level (NOAEL) for developmental toxicity of levamlodipine benzenesulfonate in fertile SD rats, their embryos, and littermates was established to be 10 mg/kg/day. Levamlodipine benzenesulfonate did not exhibit significant genotoxicity.
Major depression is a mood disorder affecting 350 million people worldwide. The disorder is characterized by depressed mood, anhedonia, decreased quality of life, deficits in cognitive functions and even suicide thoughts. Treatment of depression is often a long process and includes taking different types and quantities of medications. Therefore, there is a need to predict the success of the SSRI treatment. Our research will examine the outcomes of the combined technologies: BNA (EEG), Eye-tracker, structural and functional MRI scans and neuropsychology tasks in patients with depression while receiving SSRI treatment. The purpose of the research is to track biomarkers and other measures, which will allow predicting the SSRI treatment's success within 4 weeks instead of 8 weeks. In addition, the investigators will attempt to categorize patients into different subgroups according to their brain activation and eye movements. This division into subgroups may contribute to the understanding of the mechanisms that account for the responsiveness to SSRI treatment and to the possibility of targeting patients with depression towards a particular treatment. From this research, the investigators aim to personalize the treatment of depression, make it more efficient and reduce the amount of time for the patient to reach an optimal responsiveness.
Subjects will receive device training and study materials (SQ pump device and up to a 7 day supply of SQ furosemide vials) on the day of randomization (study day 0) and discharged within 24 hours. Subjects will be discharged with planned treatment of 80 mg subcutaneous furosemide injection over 5-hours either QD or BID, depending on anticipated diuretic requirements.
A multi-center, prospective, randomized clinical trial will be conducted, of comparing sequential oocyte IVM system with traditional oocyte IVM system for high OHSS risk PCOS patients (AMH\>5.6ng/ml). The inclusion criteria will be infertile patients diagnosed by the Chinese PCOS criteria, aged below 35 years, and without other known factors interfere reproductive or metabolic functions. 300 PCOS patients will be included and randomized into either of two groups: group A will administrate sequential oocyte IVM system and group B will administrate traditional standard oocyte IVM system. The comparison will be made between groups, and both groups are conducted with the HMG administration and embryo vitrification freezing. The primary outcome of the study is live birth rate. The embryo development and pregnancy outcomes will be followed up and compared between groups.
The present invention relates to a brain tonifying capsule which prepared by ginsengs, atractylodes rhizomes, atractylodes rhizome extracts, acanthopanax root extracts, epimedium extracts, wolfberry fruit extracts, thyroid powder, pig spinal cord powder, lysine, zinc sulfate, ferrous sulfate, copper sulfate, vitamin, nicotinamide and calcium pantothenate. Vitamin B1 and vitamin B2 are mixed to made a granule I; vitamin E is made into a microcapsule; vitamin B6, the lysine, the nicotinamide, the thyroid powder, the zinc sulfate, the ferrous sulfate, the copper sulfate, the ginsengs, the atractylodes rhizome and the Calcium pantothenate are respectively pulverized into fine powder, then are evenly mixed with the pig spinal cord powder, and then the four extracs and molding supplementary materials are added in. The mixture is evenly mixed and is made into a granule II. Finally, the granule I, the granule II and the vitamin E microcapsule are evenly mixed and assembled into capsules. The product uses biological products, microelements and microbes as the main raw materials to make Chinese patent drugs, which has no side and venenous effect and convenient administration, and can enhance intelligence, improve intelligence quotient, promote the development of brains, and enhance intellectual rehabilitation. The present invention has fast earnings and obvious effect.
FIELD: medicine. SUBSTANCE: method particularly relates to pharmaceutical industry. According to method, dry seaweed raw material is initially subjected to extraction treatment by water-alcohol mixture. Performed is separation of extracts from cake, separation of mannitol and mineral complex from water-alcohol phase, and separation of alginate from cake. Dry vegetative raw material is subjected to extraction simultaneously by oil or fat and water-alcohol mixture at following proportioning of components: dry vegetative raw material 1, oil or fat 3-40, ethyl alcohol 1.5-15, water 1-30. After that, separated is oil or fat phase. Used in function of dry seaweed raw material is thallus of laminaria. Application of aforesaid method allows for producing high-quality products for use in medicine and cosmetology. EFFECT: high efficiency. 5 cl, 2 tbl
Office-based Opioid Treatment (OBOT) is the primary care or ambulatory care provision of medication assisted treatment (MAT) for patients suffering opioid use disorder (OUD). MAT with buprenorphine in primary care clinics is a proven strategy to treat opioid use disorder (OUD) and is slowly becoming accessible to patients through primary care. Treating patients with buprenorphine involves an initial induction, during which patients discontinue their opioids, begin withdrawal, and receive the first few doses of buprenorphine. National guidelines for OBOT have focused on observed, office-based induction to begin MAT. Over the years, unobserved, home MAT inductions have also been used and shown to be safe and effective. Individually, each induction strategy is evidence-based, guideline concordant care. In light of the current COVID-19 pandemic, inductions are also being conducted via telehealth using synchronous audio or video observation. Most research, on which the current guidelines are based, examined short-term outcomes. However, OUD is a chronic condition. MAT often involves intermittent return to illicit opioid use and treatment lapses, resulting in multiple attempts to remain in long-term treatment. Important differences between the activities that occur during home, office-based, and telehealth induction might influence short-term stabilization, long-term maintenance treatment, and quality of life outcomes. No large-scale, multi-center, randomized comparative effectiveness research has compared induction method on long-term outcomes for patients suffering from OUD seen in primary care settings.There is currently insufficient evidence to recommend home induction (asynchronous, unobserved), office induction (synchronous, observed), or telehealth induction (synchronous phone or video contact, observed).

Acknowledging the dire need for increased access to effective treatment for OUD, patients and providers are eager to better understand if home, office-based, or telehealth induction in the primary care setting leads to more successful short-term stabilization and long-term maintenance treatment and patient outcomes. They also question whether certain patient characteristics, such as substance use history, executive function, and social determinants of health, are associated with better long-term outcomes in patients receiving one method versus the others. We propose a comparative effectiveness research study, randomized at the patient level, to compare short-term stabilization and long-term maintenance treatment outcomes of home induction (asynchronous, unobserved), office induction (synchronous, observed), or telehealth induction (synchronous phone or video contact, observed) for patients suffering from OUD and opioid dependence.
We have a reason to value the Uniform Determination of Death Act (UDDA). Since enactment, the UDDA has been of paramount importance to US citizens, families of comatose patients, and the health care professionals who care for them. The UDDA sets forth two standards for determining death and leaves to the medical community to elaborate criteria by which physicians can determine when those standards have been met. Neurologists and neurocritical care experts always have been center stage in this effort. Perfectly established, why change it? What ignited the recent review of the UDDA were lawsuits questioning medical (neurological) authority leading to the wording and accuracy of the UDDA being revisited. The major objections to the language of the UDDA by several groups led a committee appointed by the Uniform Law Commission to consider several substantial changes in the Act. After several years of discussion without reaching a consensus, the committee's chair suspended the effort. Upending the UDDA will lead to a legal crisis and confusion across the states. We present our main arguments against revising this statute and argue that the committee's failure to revise the UDDA should actually be seen as a necessary success.
A medical implant for injecting into the vascular system of animals comprises a device less than 500 μm in size carrying signal processing means for providing an output in response to an input signal. The input may be acoustic, electromagnetic, temperature, pH value, or chemical. The output may be acoustic, electromagnetic, or chemical. Large numbers, e.g., 10 8 , of the implant devices may be mixed into a saline solution and injected into a blood vessel where they are carried around the vascular system, or the devices may be mixed with a gas and inhaled. The amount of circulation depends on the device size. For the larger device e.g., above 7 μm to around 250 μm, circulation will be short lived. Smaller sized e.g., <3 μm devices will circulate for a considerable time. Anti-bodies may be coated onto the devices to cause them to adhere to target areas such as tumors. In one device a chemical is released when illuminated externally by an acoustic beam. In another device a chemical is released when the pH of surrounding blood changes to a given level. Power to operate the device may be by an integral battery.
Evamist (estradiol transdermal spray) is designed to deliver estradiol to the blood circulation following topical application to the skin of a rapidly drying solution from a metered-dose pump.

Evamist is a homogeneous solution of 1.7% estradiol USP (active ingredient) in alcohol USP and octisalate USP formulated to provide sustained release of the active ingredient into the systemic circulation.

Estradiol USP is a white crystalline powder, chemically described as estra-1,3,5(10)-triene- 3,17β-diol. It has an empirical formula of C18H24O2•1/2 H2O and molecular weight of 281.4. The structural formula is:

Each metered-dose pump contains 8.1 mL and is designed to deliver 56 sprays of 90 mcL each after priming. One spray of Evamist contains 1.53 mg estradiol. The metered-dose pump should be held upright and vertical for spraying. Before a new applicator is used for the first time, the pump should be primed by spraying 5 times with the cover on.

One, two or three sprays are applied daily each morning to adjacent non-overlapping 20 cm2 areas on the inner surface of the arm between the elbow and the wrist and allowed to dry.
The disclosed is directed to certain polymorphs and forms of crystalline (2-Benzhydryl-1-azo-bicyclo[2.2.2]oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-amine citrate and their pharmaceutical composition.  The citrate salt is a CNS active NK-1 receptor antagonist and the disclosed is directed to methods of treating conditions affected or facilitated by a decrease in substance P mediated neurotransmission. Two crystalline polymorphic forms of (2-Benzhydryl-1-azo-bicyclo[2.2.2]oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-amine citrate monohydrate (the monohydrates) are described. The pharmaceutical composition containing at least one of these polymorphs has advantageous stability for formulation to treat acute emesis in-patient receiving chemotherapy. The administration of this pharmaceutical composition is conventionally oral by preferably tablet or capsule and intravenous means.  Methods of making crystalline polymorphic are also disclosed.
MinnelideTM Capsules will be given orally once daily x 21 days in combination with protein-bound paclitaxel given intravenously on days 1, 8 and 15 in patients with pancreas and breast cancer. One cycle will equal 28 days. MinnelideTM Capsules should be given with the patient in a fasting state.
The present invention provides synthetic resin tooth material containing retention appearance inorganic filler and a manufacturing method thereof. The filler is composed of powder and liquid, wherein the powder is a methacrylic ester bead polymer of the retention appearance inorganic filler, and the range of the average particle diameter of the powder is from 20 to 200 micrometers. The main components comprises 5 to 25% of retention appearance inorganic filler, 0 to 20% of barium aluminum silicate glass and/or 0 to 5% of micro silicon dioxide and 75 to 95% of methacrylic ester resin. The liquid is a methyl methacrylate monomer or a methyl methacrylate common monomer. A mixture of the powder and the liquid is solidified and formed according to a conventional powder / liquid polymerization technique. Synthetic resin teeth made from the material not only can imitate natural teeth in the aesthetic performance such as colors, transparence, appearance, etc. but also have excellent abrasion performance.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely to oncology and surgery, and can be used in treating malignant gastric and duodenal tumours. That is ensured by diagnostic angiography, detecting arteries mainly feeding gastric and duodenal tumour zones. Then a chemopreparation in Lipiodol 0.5-1.0 ml is introduced in a gastroduodenal and/or left or right gastric and/or gastroomental arteries with using no more than 1/3 of a single dose. The treatment is carried out not at least 1 time a month. ^ EFFECT: method allows providing effective regional chemotherapy with a minimum toxic effect on the patients suffering said pathology with simultaneous decrease in chemopreparation and Lipiodol dose decline. ^ 3 cl, 2 ex